FDA Approves Another Generic Abortion Pill, Drawing Criticism
FDA approves another generic version of abortion pill mifepristone, drawing criticism from conservative groups and lawmakers. Evita Solutions announced the approval, which will increase access to the drug.
The FDA's decision comes after years of delays and reviews. Evita Solutions initially filed its application in 2018. The drug, originally approved in 2000, has seen gradual access expansion over time. However, access remains restricted in many states due to local laws.
The approval process faced criticism from Students for Life Action and Republican Sen. Josh Hawley. They argue that FDA officials have limited discretion in deciding whether to approve generic drugs. Meanwhile, Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary had pledged to review mifepristone's safety. Evita Solutions expects the drug to launch in January 2023.
The FDA's approval of Evita Solutions' generic mifepristone will provide a lower-cost alternative, potentially increasing access to the drug. Despite criticism, the move aligns with the FDA's mission to promote public health.
